Clinical trials / NCT07221500
NCT07221500Phase 2Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

Study sponsor: Nurix Therapeutics, Inc. · NRIX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2028-01Estimated
Enrollment · participants100Estimated
Source updated2026-09-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Objective response rate as determined by an Independent Review Committee (IRC)

+ After

Measure: Objective response rate without partial response with lymphocytosis (PR-L) as determined by an Independent Review Committee (IRC)

Check registry source